MindMaze Therapeutics backs University of Pittsburgh trial combining spinal cord stimulation with intensive neurotherapy to enhance durable stroke recovery
Executive summary: MindMaze Therapeutics announced it is supplying its spinal cord stimulation technology to support a University of Pittsburgh clinical trial that evaluates whether adding stimulation to an intensive neurotherapy regimen can make short‑term arm movement improvements after stroke durable. Demonstrating lasting benefits from a combined neuromodulation‑therapy approach could shift stroke rehabilitation standards, create new reimbursement opportunities, and expand the market for integrated neuro‑rehab solutions.
Who is involved: MindMaze Therapeutics (technology provider), University of Pittsburgh researchers (study sponsors), and stroke patients participating in the trial.
Likely next: The trial will enroll participants over the next 12 months, with primary efficacy results expected for presentation at a major neurology conference in mid‑2027.
The study aims to test whether pairing cervical spinal cord stimulation with high-dose, high-intensity neurotherapy can translate immediate motor improvements into lasting functional gains for stroke survivors. MindMaze's neurotechnology platform provides the stimulation and therapy delivery, highlighting growing interest in neuromodulation‑rehabilitation combos. If successful, the approach could inform future reimbursement pathways and drive demand for integrated neuro‑rehab devices in the post‑acute care market.
Timeline
- — MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy (PR Newswire)
Key entities
Sources
Open the full interactive case file on Beyond →
INTELLIGENCE
Social Pulse
AI estimate · not scraped